biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 5.2

an Open Access Journal by MDPI

# Treatment for Pulmonary Fibrosis

Guest Editors:

**Prof. Dr. Hiroshi Mukae**
Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

**Dr. Noriho Sakamoto**
Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Deadline for manuscript submissions:
**closed (15 December 2022)**

## Message from the Guest Editors

Dear Colleagues,

Pulmonary fibrosis is characterized by excessive deposition of extracellular matrix and destruction of the pulmonary parenchyma. The cause or contributing factor of pulmonary fibrosis is often unknown, and some diseases including idiopathic pulmonary fibrosis have poor prognosis despite treatment. Recently, progressive fibrosing interstitial lung disease (PF-ILD) has been advocated to this phenotype, but there are many uncertainties and problems to be resolved in the term “PF-ILD”.

This Special Issue “Pulmonary fibrosis: From pathogenesis to therapeutics” will focus on the novel approaches to the pathogenesis, diagnosis, and therapeutics of pulmonary fibrosis at basic to clinical levels.

Dr. Hiroshi Mukae
*Guest Editor*

# biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 5.2

an Open Access Journal by MDPI


## Editor-in-Chief


**Prof. Dr. Felipe Fregni**

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA


## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.
**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us


*Biomedicines* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI